The promising impact of molecular profiling on treatment strategies in oral cancers

J.-P. Foy a,b,c,*, P. Saintigny b,c,d, P. Goudot a, T. Schouman a, C. Bertolus a

a Service de chirurgie maxillo-faciale et stomatologie, université Pierre-Marie-Curie–Paris 6, hôpital Pitié-Salpêtrière, 75013 Paris, France
b INSERM U1052, CNRS 5286, centre Léon-Bérard, centre de recherche en cancérologie de Lyon, université Lyon, université Claude-Bernard-Lyon-1, 69008 Lyon, France
c Département de la recherche translationnelle et de l’innovation, centre Léon-Bérard, 69008 Lyon, France
d Département d’oncologie médicale, centre Léon-Bérard, 69008 Lyon, France

1. Introduction

Head and neck cancers are commonly squamous cell carcinomas and are due to excessive alcohol consumption and smoking exposure. Head and neck squamous cell carcinoma (HNSCC) is the 7th most common cancer with a worldwide incidence exceeding half a million cases annually [1]. The past decade has witnessed significant advances in head and neck reconstructive surgery with the increasing use of perforator flaps [2], in radiation strategies with intensity-modulated radiotherapy (IMRT) [3] and in the management of metastatic/recurrent HNSCC with the promising impact of immunotherapies [4,5]. However, HNSCC remain a major cause of cancer-associated mortality and morbidity, particularly oral cavity SCC, the most common anatomical subsite of HNSCC. Oral squamous cell carcinoma (OSCC) is associated with the greatest risk of death [6], commonly related to locoregionally advanced disease [7]. Because OSCC may develop from oral premalignant lesions (OPL), the most common one being oral leukoplakia (OL), prevention of OPL malignant transformation as well as early detection of oral cancer may substantially improve outcome.

The development of new technologies for molecular profiling, such as next generation sequencing (NGS), has allowed providing a comprehensive molecular characterization of a wide variety of tumor types including OSCC [8,9]. Overall, this accumulated knowledge is an opportunity to make precision medicine a clinical reality [10]. Deciphering the molecular mechanisms associated with oral carcinogenesis may help move the field of OPL and OSCC management into the new era of precision medicine/surgery.

In this article, we describe the main molecular alterations occurring during oral carcinogenesis and discuss how molecular medicine is thought to change our current vision of OPL and oral cancer care.

2. Molecular characterization of oral carcinogenesis

2.1. A multistep process

Oral carcinogenesis is commonly described as a multistep process corresponding to the accumulation of genetic events driving the transformation of a normal mucosa into an invasive carcinoma. The so-called “genetic events” includes a large panel of molecular alterations including somatic mutations and copy number alterations (amplification, deletion) of tumor suppressor genes or oncogenes [11], epigenetic changes i.e. aberrant DNA methylation, histone modifications and miRNA deregulations [12].

* Corresponding author at: service de chirurgie maxillo-faciale et stomatologie, hôpital Pitié-Salpêtrière, 47-83, boulevard de l’Hôpital, 75013 Paris, France.
E-mail address: jphilippefoy@gmail.com (J.-P. Foy).

http://dx.doi.org/10.1016/j.jormas.2017.05.004
2468-7855 © 2017 Elsevier Masson SAS. All rights reserved.
and gene/protein based pathways deregulation, that have been reported during oral carcinogenesis. Some of these alterations that accumulate during tumor development may confer to clonal population of cells selective advantages for tumor progression, and are therefore considered as drivers of tumorigenesis. They confer distinctive and complementary biological capabilities, named cancer hallmarks, that enable tumor growth, invasion and metastatic dissemination [13]. Those include genomic instability, immune escape, angiogenesis, resistance to apoptosis, or replicative immortality. The variety of molecular events may affect the expression and function of thousands of genes and proteins, and explain the remarkable diversity and complexity of neoplastic diseases.

Researchers proposed a model of tumor progression, which includes driver and sequential molecular alterations, and is commonly referred as “vogelgram”, in reference to the first publication by Vogelstein et al. [14]. A “vogelgram” has also been described in HNSCC [15]. This genetic progression model that includes successive chromosomal losses at specific loci during head neck carcinogenesis (i.e. normal > hyperplasia > dysplasia > carcinoma in situ > SCC), has also provided some insight into the field carcinization concept, a phenomenon by which an entire field of tissue exposed to a defined carcinogen, may develop premalignant and malignant changes [16,17]. The concept of field carcinization and multistep carcinogenesis form the basis of chemoprevention. Most of the literature in this field has focused on the easily accessible oral cavity [18], with various clinical presentations (leukoplasia, erythroplasia, lichen planus...) grouped as oral premalignant lesions (OPLs) [19]. Most of the publications in the oral cancer prevention field refer to oral leukoplakia (OL), the most common OPL [19,20].

2.2. Molecular alterations at early steps of oral carcinogenesis

Because OL is easily accessible to physical examination, oral carcinogenesis is a good model for prevention. However, its clinical natural history remains poorly understood [21], the reported rate of malignant transformation is highly variable, from 0% to 36% [20,22]. Additionally, the presence and the degree of dysplasia observed in OL is inconsistently associated with the risk of oral cancer development for several reasons:

- OL without dysplasia may still progress to cancer;
- a high inter- and intra-observer discordance rate has been reported in the evaluation of dysplasia;
- and OL may be reversible even when dysplasia is identified [23].

The poor value of clinical and pathological factors to predict the risk of malignant transformation of OL has provided the rational to develop molecular-based prevention strategies.

The most robust and validated biomarker of oral cancer risk is loss of heterozygositities (LOH) at specific chromosomal loci, first reported by Mao et al. in 1996 [24], and subsequently validated by larger retrospective and prospective studies [25–27]. Other biomarkers of risk have been proposed such as deltaNp63 and podoplanin increased protein expression [28,29], as well as AGTR1, FOX2 and PENK increased promoter methylation and decreased global DNA methylation [30]. Gene expression profiles have been shown to be altered early during oral tumorigenesis and associated with oral cancer development [31,32]. The underlying stroma and its interaction with the epithelium may also play an important role during oral carcinogenesis. Indeed, a low CD3+ T cells infiltrate [33] as well as a declined inflammatory phenotype [34] have been associated with malignant transformation of OPL.

Overall, key-molecular events occur at early steps of oral carcinogenesis that result in an increased risk of OPL malignant transformation. A comprehensive molecular characterization of OPLs and paired OSCC is now required to allow an integrated molecular analysis of these molecular alterations. This effort will allow proposing a comprehensive model of longitudinal molecular changes occurring during oral carcinogenesis and will hopefully help refining prevention strategies.

2.3. Molecular characterization of oral squamous cell carcinomas

Compared to most other cancer types, HNSCC harbor a high level of somatic mutations [35–37]. Genomic instability, as defined by high levels of CNAs and mutations, is a dominant feature of OSCC. At the chromosomal level, more than 50% of OSCC harbor arm-level CNAs, particularly gains of 8q (63%) and 3q (58%), as well as losses of 3p (76%) and 18q (56%) [8]. At the gene level, focal deletions occur in chromosomal region 9p that contains the tumor suppressor gene CDKN2A, whereas focal 11q amplifications is associated with overexpression of CCND1, FADD, ORAOV1, IKBKB and BIRC2 [8]. EGFR demonstrates a high-level amplification in more than 10% of samples and is overexpressed in a majority of HNSCC, leading to the development of EGFR inhibitors, including cetuximab, the only approved targeted therapy in locally advanced or advanced HNSCC. Additionally, some mutations are common in OSCC, particularly inactivating mutations of FAT1 (30%) that play an important role in cell differentiation and cell growth, CASP8 (10%), and the tumor suppressor gene TP53 (60%). Interestingly, recurrent NOTCH1 mutations have been reported, that may be associated with loss-of-function especially in Caucasians [38] or with gain-of-function in the Chinese population [39], underlining the complexity of some molecular alterations occurring during oral carcinogenesis.

At the pathway level, mitogenic signaling including EGFR, HRAS and PIK3CA, cell cycle, and TP53 pathway were altered in most of OSCC. Additionally, epithelial-to-mesenchymal transition as well as degradation of the extra-cellular matrix are frequently altered during oral carcinogenesis particularly in oral tongue SCC [40].

In order to provide an integrated overview of these molecular alterations, HNSCC have been classified into distinct molecular subtypes [41–43]. The classification into 4 subtypes (atypical; basal; classical and mesenchymal subtypes) is the most commonly used [9,44,45]. In this classification based on gene expression profiles, the “classical”, “basal” and “mesenchymal” subtypes exhibit canonical genomic alterations such as focal EGFR amplification, high frequency of HRAS mutations and upregulation of EMT-related genes respectively, while the atypical subtype is characterized by PIK3CA activating mutations and the lack of chromosome 7 amplification. Using data from The Cancer Genome Atlas (public repository), we show the distribution of those molecular subtypes in OSCC and other HNSCC (Fig. 1). In the oral cavity, the basal (42.7%) and the mesenchymal (34.8%) are the two main subtypes.

3. The impact of molecular profiling to refine treatment strategies of oral cancer

While the 20th century was marked by significant medical advances particularly in diagnosis imaging, molecular medicine may be one of the breakthroughs of the early 21st century. Indeed, since the first draft of the human genome sequence published in 2001, the dramatic decrease of sequencing cost as well as the development of new technologies such as next generation sequencing allowed generating huge amounts of data, commonly named “big data”, in the field of molecular oncology [46]. The
In the prevention field, precision medicine may also play a pivotal role in the future. The recent clinical trial Erlotinib Prevention of Oral Cancer (EPOC) was the first randomized chemoprevention trial to utilize molecular risk stratification as a core selection strategy [27]. In this study, patients with OPL or who underwent surgical resection for OSCC, were stratified by their risk of oral cancer as defined by LOH status in OPL or normal mucosa. High-risk patients were randomized to the EGFR tyrosine kinase inhibitor erlotinib arm or to the placebo arm. Although the trial did not reach its primary objective, it allowed validating LOH status as a robust biomarker of oral cancer risk. Markedly, as previously described by J.E. Bauman and J. Grandis, EPOC marked “the beginning of an epoch of molecular selection” [51] and moved forward the oral cancer prevention field.

3.2. Radiation strategies

Radiotherapy plays a major role in the management of HNSCC and benefits approximately 75% of patients with HNSCC [52]. However, the complex anatomy of the upper aerodigestive tract makes it difficult to safely deliver an efficient dose to the tumor. Although different molecular mechanisms or biomarkers have been associated with radiosensitivity/radioresistance in HNSCC [53–56], precision medicine in radiation oncology has been poorly studied. HPV-positive oropharyngeal tumors are associated with a higher radiosensitivity, thought to be linked to specific molecular alterations such as p16 overexpression that decreases DNA repair capacities by inhibiting the recruitment of RAD51 to the site of DNA damage [57]. Based on this rational, de-escalation treatment protocols are currently being evaluated in clinical trials in this setting, with the goal to decrease morbidity without decreasing efficacy [58–60]. Similarly, because some specific molecular alterations such as activation of the EGFR have been associated with radioresistance in HPV-negative HNSCC [61,62], it is tempting to envision similar approaches based on biological differences across HPV-negative HNSCC.

Interestingly, a study has shown the relevance of a Genome-based model for Adjusting Radiotherapy Dose (GARD) to tumor radiosensitivity. GARD is derived from a gene expression-based radiation sensitivity index previously proposed in HNSCC [63] and a linear quadratic model. A high GARD value predicted a higher therapeutic effect of radiotherapy in a large cohort of patients suffering from different types of cancer. Interestingly, median GARD was higher in patients with oropharyngeal SCC compared to non-oropharyngeal HNSCC. Thus, the GARD may serve as the basis for precision medicine in radiation of HNSCC.

3.3. Surgical strategies

Because oral cavity is a complex anatomical site critical for speech, swallowing and appearance, oral cancer surgery is associated with two main challenges:

- to perform a complete resection of the tumor disease (R0), including the primary tumor site and regional lymph nodes to cure patients;
- and to perform a functional and esthetic reconstruction to improve quality of life of patients.

3.3.1. Margin

Positive margins are recognized as a strong poor prognostic factor in OSCC [64–67]. As previously described [68], intraoperative...
guidance is primarily based on human vision and tactile information, especially for peroperative margin assessment. In order to control margin without resecting unnecessary normal tissue, 0.7 cm was described as the ideal distance in oral squamous cell carcinomas [64]. However, a millimeter accuracy remains a challenge for the surgeon, and one centimeter is the usual distance approximately measured around the tumor to perform resection. Additionally, although histopathology is the gold standard for margin assessment, peroperative pathologic assessment of the margin status can be difficult because of tissue shrinkage, inaccurate sampling, and improper orientation [66]. Furthermore, correlation of orientation/localization between the tumor and tumor bed are distorted after excision [69]. Interestingly, the use of biomarkers such as a gene expression signature [70] or p53 and eIF4E immunohistochemical expression [71] have been proposed in histologically negative margin to predict recurrence. Whether reproducible molecular margin assessment is associated with improved prognosis needs to be further validated prospectively.

Several technologies for intraoperative tumor visualization have been recently described [72]. Optical fluorescent imaging, based on fluorescence variation between normal and tumor tissue, requires a fluorophore agent, which is autogenous (autofluorescence) or exogenous (fluorescent probes). Compared to non-targeted fluorescent probes (e.g. indocyanine green), targeted fluorescent probes (corresponding to specific molecules) may be more specific to tumor tissue and improve accuracy. Targeted fluorescent probes are selected according to “Target Selection Criteria” (TASC) scoring system, including percentage of target overexpression as well as its tumor/normal cell ratio [72]. Overall, the main goal is to target relevant biomarkers of cancer corresponding to the previously published cancer hallmarks [73]. A comprehensive molecular profiling of OSCC may help for the identification of the best candidates for targeted-probe fluorescence imaging using near-infrared. A recent paper showed the relevance of the Gastrin Releasing Peptide Receptor (GRPR) and its binding peptide TM1-IR680, for surgical margin prediction in a murine orthotopic model of oral cancer [74].

An alternative approach for refining margin resection strategies may be to predict the preoperative probability of positive margins, as previously described in breast cancer [75]. Molecularly-based preoperative assessment of the probability of positive margin according to the tumor biology may therefore refine surgical strategies, particularly the classical one centimeter margin.

3.3.2. Nodal involvement

Cervical lymph node dissection is a well-established treatment in clinically node-positive (cN+) OSCC. In early-stage (cT1-T2) and cN0 OSCC, an elective neck dissection should be performed when the probability of occult nodal disease is greater than 20% [76]. Interestingly, the incidence of occult cervical metastasis was 9.8% in hard palate and maxillary alveolar SCC [77] while buccal OSCC were associated with a rate of 1.8% and 10.6% for cT1 and cT2 tumors respectively. Based on these results, a “watchful waiting” strategy has been proposed for early stages SCC of the hard palate and maxillary alveolar.

A tumor gene expression signature has been proposed to be associated with lymph node metastases in HNSCC [78] and then validated in OSCC for prediction of lymph node positivity [79]. Interestingly, the negative predictive value of this signature was higher in early-stage OSCC (89%), the most relevant subset of OSCC in the context of node metastasis prediction. Thus, preoperative molecular assessment of the probability of occult disease may refine surgical strategies in early-stage OSCC from the hard palate and maxillary alveolar.

4. New technologies may bridge the gap between basic research and clinical practice

Because most of the studies described above have been performed in frozen samples and a research context, their main pitfall is their relevance in routine practice. In order to transfer those advances in molecular-driven medicine including radiation, targeted therapies as well as surgical strategies, new technologies able to address the challenges associated with molecular profiling of formalin fixed paraffin embedded (FFPE) patient samples have been developed that allow targeted DNA/RNA sequencing. They may help bridging the gap between basic research and clinical practice.

As part of this effort, we have initiated the “Cavity Oral Squamous Molecular Screening” (COSMOS) project (Fig. 2) to make clinical use of the molecular information generated by new sequencing technologies dedicated to FFPE samples. This is a collaborative project between the department of translational research at Centre Léon-Bérard (Lyon, France), the department of maxillo-facial surgery and the department of pathology (Pr I. Brochériou, Dr G. Hervé) at Hôpital Pitie-Salpêtrière (Paris, France). Using the HTG Edge Seq technology (HTG Molecular Diagnostics, Tucson, AZ, USA), we are currently generating targeted-gene expression profiles of OSCC to identify therapeutic targets, and to assess the relevance of gene expression signatures associated with radiosensitivity, margin positivity, and lymph node metastasis (Fig. 3). Using only one 5 μm tumor section, this technology allows generating targeted-gene expression profiles in FFPE samples (~2 days and less than 4 hours hand-on-time, for 96 samples). The expression levels of a panel of ~2560 genes involved in cancer hallmarks are measured in a single experiment, in a specific area of the tumor selected by a pathologist on an adjacent HES stained slide.

In conclusion, recent insights into the molecular comprehension of oral carcinogenesis as well as the development of new molecular profiling technologies available in clinical routine may

![Fig. 2. Cavity Oral Squamous Molecular Screening (COSMOS). COSMOS is a collaborative project between the department of translational research at Centre Léon-Bérard (Lyon, France), the department of maxillo-facial surgery and the department of pathology (Pr I. Brochériou, Dr G. Hervé) at Hôpital Pitie-Salpêtrière (Paris, France). Our goal is to make clinical use of the molecular information generated by new sequencing technologies dedicated to FFPE samples, in order to refine treatment strategies in oral cancers.](http://dx.doi.org/10.1016/j.jormas.2017.05.004)
allow refining treatment strategies in patients suffering from OPL and OSCC. Thus, precision medicine and surgery may decrease the substantial morbidity and mortality associated with oral cancer.

Disclosure of interest

The authors declare that they have no competing interest.

References

[34] Woodford D, Johnson SD, De Costa AM, Young MR. An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol 2014;5(3).


Fig. 3. Targeted-RNA sequencing using the HTG EdgeSeq technology. The HTG EdgeSeq technology requires only one 5 μm section for generating targeted-gene expression profiles in FFPE samples. The expression levels of a panel of ~2500 genes involved in cancer hallmarks are measured in a single experiment, and may be used in precision medicine and surgery.